PBYI Stock Analysis: Buy, Sell, or Hold?
PBYI - PUMA BIOTECHNOLOGY INC
$9.24
0.13 (1.43%)
▲
5d:
+4.64%
30d:
+15.36%
90d:
+31.06%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PBYI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PBYI shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.00
Based on -16.2% avg growth
INTRINSIC VALUE TODAY
$1.24
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $9.24, which is considered extended relative to its 30-day fair value range of $7.92 to $8.94. From a valuation perspective, the stock is trading at a premium (Forward PE: 26.0) compared to its historical average (14.9). At these levels, the market is pricing in 20.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PBYI is in a uptrend. The price is approaching resistance at $9.51. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PBYI scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $6.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PBYI is in a uptrend. The price is approaching resistance at $9.51. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PBYI scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $6.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.92 -
$8.94
Company Quality Score
39/100
(SELL)
Options IV Signal
45th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
28.1%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 45th percentile)
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 34.1% above Wall St target ($6.00)
- NEUTRAL: Trading at premium valuation - market expects 20.4% growth which is achievable
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.92 -
$8.94
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.71
(18.5%)
Support & Resistance Levels
Support Level
$8.48
Resistance Level
$9.51
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.03
Wall Street Target
$6.00
(-34.1%)
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
35.8%
Profit Margin
11.6%
Valuation Premium vs History
+20.4% premium
PE vs Historical
26.0 vs 14.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+20.4%
(market-implied from PE analysis)
1-Year Target
$10.97
(+20%)
2-Year Target
$13.21
(+45%)
3-Year Target
$15.90
(+75%)
3-Yr Target (if PE normalizes)
(PE: 26→15)
PE COMPRESSION
$9.10
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.0, Growth: -36.4%)
$6.64
(+-27%)
Base:
(SPY PE: 20.1, Growth: -36.4%)
$5.12
(-44%)
Bear:
(PE: 14.9, Growth: -36.4%)
$3.80
(-58%)
📈
Valuation based on Current Earnings
Trailing PE: 18.25 | Current EPS (TTM): $0.52
Bull Case
$7.03
(-24%)
Analyst growth -32.7%, PE expands to 20.1
Base Case
$6.39
(-31%)
Market implied -32.7%, PE stable at 18.3
Bear Case
$6.45
(-30%)
Severe decline -20.0%, PE contracts to 15.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 7:38 PM ET
Data refreshes hourly during market hours. Next update: 8:38 PM
Data refreshes hourly during market hours. Next update: 8:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$52 | 42 HOLD |
